1. Home
  2. RERE vs ANNX Comparison

RERE vs ANNX Comparison

Compare RERE & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATRenew Inc.

RERE

ATRenew Inc.

SELL

Current Price

$4.37

Market Cap

832.8M

ML Signal

SELL

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$4.31

Market Cap

726.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RERE
ANNX
Founded
2011
2011
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
832.8M
726.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
RERE
ANNX
Price
$4.37
$4.31
Analyst Decision
Strong Buy
Buy
Analyst Count
4
10
Target Price
$6.64
★ $17.00
AVG Volume (30 Days)
444.0K
★ 3.5M
Earning Date
11-19-2026
11-17-2026
Dividend Yield
★ 2.44%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$27.40
N/A
Revenue Next Year
$21.96
N/A
P/E Ratio
$34.57
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.50
$2.54
52 Week High
$6.47
$7.18

Technical Indicators

Market Signals
Indicator
RERE
ANNX
Relative Strength Index (RSI) 57.09 55.99
Support Level $3.79 $3.71
Resistance Level $4.09 $4.37
Average True Range (ATR) 0.14 0.27
MACD 0.02 0.06
Stochastic Oscillator 88.46 95.43

Price Performance

Historical Comparison
RERE
ANNX

About RERE ATRenew Inc.

ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: